Kevin Kunzmann

Data show age may be a significant effect on results from contact dermatitis patch tests.

The ustekinumab biosimilar will be available in early 2025, with indications to treat psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.

The latest episode of Lungcast explores the evolving field of pulmonary imaging technology and the transformative impact of artificial intelligence.

The approval to GE Healthcare's cyclotron-produced radioactive diagnostic drug provides another option to adequately identify significant coronary artery disease.

Amanda Wilson, PhD, details how her team is developing risk assessment models to evaluate viral infection intervention in schools.

Georgios Kitsios, MD, PhD, discusses his team's interim results an analysis that is providing insights into the microbiome dynamics of critically ill patients with VAP.

Kerri Aronson, MD, MS, describes her team's research efforts to create educational resources that address the profound lack of patient knowledge around HP.

Here's what to expect from the new pulmonology research quarterly newsletter powered by the American Lung Association Research Institute.

Identified proteins impacted by the presence of atopic dermatitis may provide clinicians a better understanding of how to treat it.

A new analysis suggests HbA1c may be more informative to fatty liver disease severity than BMI, and should be included in screenings.

Mora and Sadreameli join Lungcast to provide a back-to-school health blueprint, including topics like rescue inhalers, vaccination, vaping and air quality.

In this exclusive deep dive, a pair of leading dermatologists highlight the new data defining ruxotitinib cream, upadacitinib, and more agents from the revolutionary drug class.

Bludorn joins Lungcast to review the increasing effects and signs of heat-related illness amid record-high temperatures.

After a busy first half to 2024, a number of high-impact FDA decisions await the healthcare industry through December.

Raj Chovatiya, MD, PhD, MSCI, and Lawrence Eichenfield, MD, review a recent trial comparing upadacitinib to dupilumab for patients with atopic dermatitis.

Raj Chovatiya, MD, PhD, MSCI, and Lawrence Eichenfield, MD, discuss recent data assessing ruxolitinib cream for patients as young as 2 years old with atopic dermatitis.

Ensifentrine, a PDE3 and 4 inhibitor from Verona Pharma, was associated with significantly improved lung function and reduced COPD exacerbations over 24 weeks.

Dubinett and Spira rejoin Lungcast for an update on their team's research into lung cancer interception.

Matthew Zirwas, MD, reviews the clinical discrepancies of certain JAK-targeting therapies and their role in dermatology patient outcomes.

Matthew Zirwas, MD, discusses the prospect of pairing JAK inhibitors like ruxolitinib cream with other disease-targeting options for conditions including vitiligo and alopecia areata.

Jennifer L. Hsiao, MD, reviews the rapidly growing inventory of investigational drugs for HS.

Matthew Zirwas, MD, explains why he believes agents like ruxolitinib cream and upadacitinib have become the optimal treatments for atopic dermatitis, hidradenitis suppurativa, and more.

Jennifer L. Hsiao, MD, discusses what the anticipated JAK inhibitors may provide to patients with HS if FDA-approved in the coming years.

Matthew Zirwas, MD, provides advice to dermatologists discussing the safety of JAK inhibitor therapies due to their controversial black box warning.

Patients with HS are getting a long-awaited influx of targeted therapies. Jennifer L. Hsiao, MD, discusses their immediate impact.

File joins Lungcast to review the ATS-IDSA 2019 guideline updates for community-acquired pneumonia, and advances to diagnostics and care.

Follow HCPLive's coverage of the full-day FDA committee meeting regarding Lykos Therapeutics' application for MDMA-assisted therapy as a novel treatment for patients with PTSD.

Ahead of the FDA decision on MDMA-assisted therapy to treat PTSD this summer, van der Kolk shares his thoughts on the logistics of care.

Emerson previews the highly anticipated FDA advisory committee this week, and Lykos' plans for rolling out MDMA-assisted therapy in the event it is approved to treat PTSD.

Analysis of the OASIS trial shows, on average, women post-menopause with vasomotor symptoms experience at least moderate rates of sleep disturbance.